This Pharmaceutical Giant Shares Soar To All-Time High Post Q3 Results, Profit Up 11% YoY

Dr Reddy's Laboratories Ltd, a leading pharmaceutical player, witnessed an impressive 11% surge in its consolidated net profit for the third quarter, propelling its shares to an all-time high. The quarter ended December 2023 showcased a net profit of Rs 1,380.9 crore, surpassing analyst expectations of Rs 1,313.2 crore, according to polls conducted by Bloomberg.

This performance marked a significant uptick from the previous year's figure of Rs 1,237.90 crore, with the company attributing the success to market share gains for existing products in North America and sustained growth in Europe. The revenue also witnessed a substantial 6.6% increase from the year-ago quarter, reaching Rs 7,214.8 crore, exceeding the estimated Rs 7,030.9 crore by brokerage polls.

Dr Reddy's Laboratories reported its highest-ever-sales in a quarter, underlining the resilience of the Hyderabad-based pharmaceutical firm in the dynamic global market. Co-Chairman & MD, G V Prasad, expressed his satisfaction, stating, "We delivered another quarter of the highest-ever sales and robust financial performance aided by new product performance and base business market share gain."

The North America business, including the United States, played an important role in this success story, recording a 9% growth in sales at Rs 3,350 crore. This growth was attributed to market share expansion in key existing products and revenue from new product launches, partially offset by price erosion. The company's sequential growth of 5% in North America was driven by a net increase in volumes in its base business.

Contrary to expectations, the domestic market in India contributed significantly with sales reaching Rs 1,180 crore, reflecting a year-on-year growth of 5%. However, there was a slight quarter-on-quarter decline of 1%, primarily due to lower volumes in the base business.

The financial report also highlighted the company's performance in Russia, where revenue stood at Rs 590 crore, signalling a year-on-year decline of 14% but a quarter-on-quarter growth of 2%. Dr Reddy's Laboratories attributed the year-on-year decline to unfavourable currency exchange rate movements and a high base business.

Despite concerns from brokerages about weak sales in the domestic market and price erosion in the US, the blockbuster cancer drug Revlimid continued to contribute stably, offsetting revenue losses from other segments.

While the sales performance impressed investors, the company's financial health was further bolstered by a 7.4% rise in EBITDA to Rs 2,210.7 crore, with the EBITDA margin expanding slightly to 29.3% from 29% in the base period.

The financial report also delved into the expenditure side, revealing that selling, general & administrative (SG&A) expenses for Q3 reached Rs 2,020 crore, reflecting a significant 12% year-on-year increase. This uptick was attributed to investments in sales and marketing, digitalization, and other business initiatives.

Research & development (R&D) expenses, however, stood at Rs 560 crore, accounting for 7.7% of the total revenue. During the quarter, Dr Reddy's filed 38 Drug Master Files (DMFs) globally, launched three new brands in India, and introduced four new products in the North American region. Additionally, the company filed two new Abbreviated New Drug Applications (ANDAs) with the US Food and Drug Administration (USFDA).

Dr Reddy's Laboratories shares were seen trading with gains of more than 4%, reaching Rs 6,099 per share on the National Stock Exchange (NSE) as of 12:30 pm. This surge capped off a remarkable year for investors, as the stock has provided returns of nearly 35% over the past twelve months.